Al18F-PSMA-HBED-CC as a novel tracer for the evaluation of prostate cancer patients with biochemical relapse: Intraindividual comparison with 68Ga-PSMA-HBED-CC

1268Objectives: 68Ga-PSMA-HBED-CC (68Ga-PSMA-611) PET/CT represents a clinically relevant and commonly used technique for the evaluation of prostate cancer patients in the setting of secondary staging for biochemical recurrence after definitive therapy. A novel tracer developed in our Centre: [18F]AIF-PSMA-HBED-CC (18F-ALF-PSMA-11), can be produced on a large scale with suitable radiochemical purity for clinical purposes. The aim of this study was to prospectively compare the diagnostic values of 68Ga-PSMA-611 versus 18F-ALF-PSMA-11 in patients with prostate cancer and biochemical relapse after initial treatment. A sample of 37 patients (median age: 67, range: 53-85 years) with biochemical recurrence after primary treatment (median PSA level: 5.0 ng/mL; range: 0.7-10.0 ng/mL) were included between March 2018 and July 2019, of whom 28 (76%) had undergone radical prostatectomy and 9 treated with radiotherapy. Within 1-2 weeks a PET/CT scan was performed with 68Ga-PSMA followed by an Al18F-PSMA scan with an average dose of 2.0 and 4.0 MBq/kg, respectively, with a 64-slice PET/CT with TOF correction. We measured the SUVmax of all abnormal foci as well as the SUVmax ratio (SR) in all coincident lesions, selecting gluteal musculature as background. Histopathology (when available), correlative imaging, and/or clinical follow-up were considered as reference standard, with a follow-up of at least 6 months after PET/CT scanning. 68Ga-PMSA and Al18F-PSMA PET/CT demonstrated abnormal fin...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: GU - PSMA PET (Poster Session) Source Type: research